The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people ...

Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual ...

Abbott has secured CE Mark for a dual glucose ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose ...

Healthcare major Abbott has launched its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, offering real-time glucose readings every minute and optional ...

This morning med tech giant Abbott announced a new deal with chronic care management company Omada Health that will integrate Abbott’s FreeStyle Libre continuous glucose monitor (CGM) with Omada's ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a ...

(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology. The REFLECT studies, funded by Abbott ...

(RTTNews) - Abbott Laboratories (ABT) has initiated a medical device correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems ...

Abbott’s first dual-analyte sensor comes as competitors are working to develop their own versions of the technology.